NEW YORK, March 12, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Boyd Gaming Corporation (NYSE: BYD), Ameristar Casinos, Inc. (NASDAQ: ASCA), Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Avon Products, Inc. (NYSE: AVP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Boyd Gaming Corporation Research Report
Boyd Gaming generated $117.5 million cash last year. However, cash outflows like major capital expenditures took a toll on their earnings. The company also cites the unpredictability of their revenues, causing them to lay off an uncertain number of employees in various parts of the country including Las Vegas. But things are far from bleak for the company. They recently finished the renovating the Kansas Star Casino, a key element of their recently concluded $1.45 billion acquisition of Peninsula Gaming LLC. The casino will provide the company a platform to access the Kansas market. Besides giving the company more diversity, another reason to conclude that the acquisition will be highly profitable is the property's recent performance. It generated a total of $173.4 million in gambling revenue from late December 2011 to November 2012, and Boyd Gaming CEO Smith expects it to provide even more revenue for the company in the future.. The Full Research Report on Boyd Gaming Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/5c85_BYD]
--
Ameristar Casinos, Inc. Research Report
Pinnacle had agreed to acquire Ameristar for $869 million in cash or $26.50 per share. However, some investors feel that the transaction may undervalue the company, mainly due to the fact that Ameristar will soon open its 500 million Lake Charles, LA project in 2014. Furthermore, analysts set a high target price for Ameristar, some even going as high as $33.00 per share. Ameristar's board is optimistic about agreeing to Pinnacle's terms, saying that the increased scale and diversification of the company will expand opportunities and provide enhancements for guests. The Full Research Report on Ameristar Casinos, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/46f2_ASCA]
--
Aegerion Pharmaceuticals, Inc. Research Report
Aegerion is the developer of Juxtapid, which treats a rare inherited cholesterol disorder called homozygous familial hypercholesterolemia. The company priced the pill between $235,000 to $295,000 per year, but could have been higher with the anticipated competition. The pill was approved unanimously by a panel of FDA officials. However, there are concerns surrounding the company, as Juxtapid is its only product, putting it in a vulnerable position. While Aegerion did make a last minute deal with development partner Catalant, it's still a far cry compared to much larger firms it competes with. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/7f1a_AEGR]
--
ISIS Pharmaceuticals, Inc. Research Report
Isis is the co-developer of Juxtapid's only competitor Kynamro, which costs less at $176,000 a year. The pill was co-developed by pharmaceutical giant Sanofi, and will be marketing it as soon as possible. However, the pill wasn't well received by both the FDA and the European Medicines Agency, though it was approved at a 9-6 vote. The EU agency cited cancer risks from the drug. Nevertheless, the drug is expected to sell as much as $400 million, with Isis getting 30 to 50 percent of the profits, depending on the total sales of the drug. The Full Research ISIS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/bf5f_ISIS]
--
Avon Products, Inc. Research Report
Avon faces several problems as of the moment: they have debt management concerns, their margins are thin, and trends are not working to favor the company's business model. To turn things around, Avon's new CEO, Sherilyn McCoy, laid out several strategies that are expected to ensure the company's future success. The plan includes reducing its overhead while simultaneously gaining better hold in the markets where it does well, like Asia and Latin America. These plans did not come at a humble price. To implement its strategies, the company had to reduce its dividend by 74 percent. It also plans to lay off 1500 employees in order to meet its plan to save $400 million a year by the end of 2015. Lastly, it will exit the South Korea and Vietnam markets, where it is not particularly growing. But despite these difficult steps, the company is confident that these will help it grow in the long term, making these sacrifices worth their price. Avon is scheduled to report its fourth quarter earnings on February 11, and we'll see if the company's strategies are working soon. The Full Research Report on Avon Products, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/3666_AVP]
--
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers
Email: press@ investors-alliance.com
Main: +1-(408)-745-7826
SOURCE Investors-Alliance